Blog

There is a comforting story about weight stigma in medicine, and it goes like this: doctors were never taught better, so teach them better. Add a module. Bring in a fat patient to speak. Show the students the evidence on why bodies differ. The next generation will be different.

Someone has now added up thirty years of attempts to do exactly that. The answer is not that it fails. The answer is more uncomfortable than failure: it works on the part that is easy to measure and easy to fake, and it does not detectably move anything else.

What was actually counted

Ravisha S. Jayawickrama and colleagues at Curtin University in Perth, with co-authors at Monash University, the University of Leeds and the Swedish School of Sport and Health Sciences, screened 3,463 journal articles and dissertations and found 67 studies that tested an intervention meant to reduce weight bias in healthcare students. Thirty-five of them reported enough data to be pooled statistically; the rest were described narratively. Together the studies cover 7,528 participants, mostly women (62 percent), average age 22.75 years, from studies published between 1991 and August 2023.

This is not news, and we are not presenting it as news. The paper went online on 8 October 2024 and appeared in the February 2025 issue of Obesity Reviews (26(2):e13847). It is simply the most complete answer currently available to a question that gets asked every time a hospital announces a training day.

Two numbers carry the paper.

Explicit bias — what students report on a questionnaire — improved a little. The pooled effect was g = −0.31, with a 95 percent confidence interval of −0.43 to −0.19. In plain terms: a small but statistically reliable shift in the intended direction.

Implicit bias — the automatic association measured by a reaction-time test — did not move. g = −0.12, confidence interval −0.26 to +0.02, p = 0.105, pooled from ten studies. The interval crosses zero, which means the data are compatible with a small improvement, with nothing at all, and with a slight worsening.

The authors grade the certainty of both results, using the standard GRADE system, as “very low”. They also record that the risk of bias in most of the individual studies was high. That is their assessment of their own evidence base, not our gloss on it.

The sentence that should be quoted more than the effect size

Buried in the results is a prediction interval for the explicit-bias finding: −0.93 to +0.31.

A confidence interval tells you how precisely the average across these studies was estimated. A prediction interval tells you what to expect from the next one. Here it says that if you run a weight-bias intervention with a new group of healthcare students, the true effect could plausibly be a large reduction, or nothing, or a modest increase in weight bias. That is what heterogeneity of 74 percent looks like when it is written out honestly.

So the pooled figure is real, and it is also nearly useless as a prediction for any specific course. Which brings us to the finding that should worry course designers most.

Nothing about the course design explained the difference

The team ran eight subgroup comparisons on the explicit-bias data: healthcare discipline, one-off versus multi-session, in person versus online, active versus passive learning, single-strategy versus multifaceted, underlying theory, which outcome measure was used, and whether students had contact with an actual fat person during the intervention — active contact, passive contact, or none.

Not one comparison came out significant. A meta-regression on the proportion of male participants found nothing either.

The honest reading of that is not “these things don’t matter”. With this few studies per cell, the analysis could not have detected moderate differences even if they existed, and the authors say as much: eyeballing the estimates, multi-session, multifaceted and active-learning formats look better, but the comparison groups are too small to trust. The reading that does hold is narrower and still awkward: after thirty years of varied designs, there is no evidence base telling anyone which design to buy. A hospital choosing between a two-hour e-learning module and a semester-long curriculum with patient speakers is choosing on intuition.

And it does not stay

Only 10 of the 67 studies followed students beyond the end of the intervention at all.

The example the authors highlight is a study by Kushner and colleagues with 127 medical students. Empathy and confidence in clinical interaction were still improved a year later. The negative stereotypes about fat patients had returned to baseline.

That is a pattern worth naming precisely, because it is easy to get backwards: the part that felt good to the clinician persisted. The part that describes the patient did not.

What the questionnaire is actually measuring

Explicit weight bias, in these studies, means a score on instruments like the Beliefs About Obese Persons Scale, the Antifat Attitudes Test, or the Fat Phobia Scale — a student ticking boxes about whether fat people are lazy, or whether obesity is within a person’s control.

Only four of the 35 pooled studies checked whether students were simply giving the answer they knew was wanted. The findings from those four were mixed, and in one of them, controlling for socially desirable responding erased the difference between the intervention group and the control group entirely. The authors are careful not to over-read four studies, and so are we. But it means the most obvious alternative explanation for a small post-course improvement in questionnaire scores — that students learned which box to tick — has barely been tested.

The implicit measure has its own problem, and the paper does not hide it. Twelve of the thirteen implicit studies used the Implicit Association Test, and the authors cite the standing criticism of it, including Ulrich Schimmack’s argument that the construct validity evidence does not support the claim that the IAT measures implicit bias at all.

Put those two limitations together and you get the real state of knowledge. The first instrument measures what a student is willing to say. The second measures a reaction time whose meaning is contested. Almost nothing measures what a student later does to a patient. The authors call for exactly that: studies that assess stigmatising behaviour, not just attitudes.

Who is speaking, and why that is worth knowing

Obesity Reviews is the journal of the World Obesity Federation, and the paper is written from inside that frame. It opens with the Federation’s projection that around 51 percent of people aged five and over will be living with overweight or obesity by 2035, uses “people living with overweight or obesity” throughout, and argues for reducing weight bias partly on the grounds that stigma worsens the conditions it is attached to.

We link it anyway, because the analysis is careful and the numbers are the numbers. But readers should know the frame, and they should know the declared interests: co-author Stuart W. Flint reports research grants and meeting support from, among others, Novo Nordisk, the Novo Nordisk Foundation and Johnson & Johnson, all declared as unrelated to this manuscript, and co-author Erik Hemmingsson reports royalties from a book on weight stigma. The first author and five others declare no competing interests.

None of that invalidates a meta-analysis. It does mean that when a paper written from the disease frame reports that anti-bias training barely works, that finding is not the one its institutional context would have preferred.

Germany just made this a “should”

In October 2024, the German Adipositas Society and its partner societies published version 5.0 of the S3 guideline on the prevention and treatment of obesity (AWMF register 050/001). For the first time it contains a dedicated chapter on stigma, and inside that chapter, recommendation 2.4:

Training curricula for the health professions involved in prevention and treatment should not only inform about the aetiology, mechanisms, prevention and treatment of obesity, but should also educate about weight-related stigmatisation and self-stigmatisation and their clinical implications, and should teach practical skills for non-stigmatising interaction with people with obesity.

It carries recommendation grade A — the strongest “should” the system has — and was adopted with 94 percent consensus. The evidence quality printed directly underneath it is “very low”, based on indirect evidence.

The guideline is not hiding this. Its own implications section states that promising results exist for at least small, short-term improvements in weight stigma among health professions, and that all meta-analyses on weight-related stigmatisation showed low methodological quality.

So Germany has now committed its health professions curricula, at the highest recommendation grade, to an intervention its own guideline describes as producing small, short-lived, poorly evidenced change. That is not a scandal. Given what stigma costs patients, acting on weak evidence is defensible, and the alternative — teaching nothing — has been tested for a century and produced the situation the guideline is responding to.

It does mean something specific for patients, though: the training is a promise made about your doctor, upstream of you, and nobody checks whether it took.

What is actually checkable

The same chapter of the same guideline contains something a patient can verify from the waiting room. Recommendation 2.2, adopted with 88 percent consensus, says facilities should provide adequate equipment — it names heavy-duty chairs and scales with a sufficient weighing range — or maintain a referral network for onward care.

That is the difference between the two kinds of measure. Whether a practice bought a chair that holds you is visible in ten seconds. Whether the doctor sitting in it completed an anti-bias module in 2019 is not visible at all, and on this evidence would not tell you much if it were.

Which is why the practical advice on this site does not run through hoping your doctor was trained well:

• When your symptom is being answered with your weight, the documentation and escalation steps are in What to Do When a Doctor Blames Everything on Your Weight.
• When you are looking for a different practice, the search criteria that actually predict weight-neutral care are in How to Find a Weight-Neutral (HAES-Aligned) Doctor.
• When the problem is discrimination rather than bad care, the legal picture is in Weight Discrimination: What It Is and What You Can Do.

The point that survives all the caveats

Thirty years of teaching produced a small, real improvement in what healthcare students are willing to say about fat patients, no measurable change in their automatic associations, no durable change in stereotypes a year out, and almost no data on behaviour.

Read carelessly, that is an argument for giving up on training. It is not. A small genuine reduction in explicit bias, spread across everyone who will treat patients for the next forty years, is worth having, and the alternative has no evidence behind it either.

Read carefully, it is an argument about where to put the weight of expectation. A course is not a safeguard. It produces an effect that cannot be predicted for any individual cohort, cannot be attributed to any particular design, and fades on the measure that matters most for how you get spoken to. If the goal is that fat patients are treated properly, the mechanisms that do that job are the ones that stay in place when everyone has forgotten the workshop: equipment that fits, referral paths, complaint routes, documentation, and rules about what may be said and done in a treatment room.

Prejudice, it turns out, is not primarily an information deficit. You cannot explain it away, and the people who study it hardest say so in their own conclusion: a real shift in implicit bias may only come from a large societal change in beliefs and attitudes towards people in larger bodies. That is a longer job than a module, and it is the one this magazine exists for.

---

Sources: Jayawickrama RS, Hill B, O’Connor M, Flint SW, Hemmingsson E, Ellis LR, Du Y, Lawrence BJ. “Efficacy of interventions aimed at reducing explicit and implicit weight bias in healthcare students: A systematic review and meta-analysis.” Obesity Reviews 26(2):e13847, published online 8 October 2024, DOI 10.1111/obr.13847, open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC11711078/ · PROSPERO registration CRD42020209407 · Deutsche Adipositas-Gesellschaft et al., “Interdisziplinäre Leitlinie der Qualität S3 zur Prävention und Therapie der Adipositas”, AWMF register 050/001, version 5.0, October 2024, chapter 2 “Stigmatisierung”, recommendations 2.1 to 2.4 and section 2.4 “Implikationen”: https://register.awmf.org/assets/guidelines/050-001l_S3_Praevention-Therapie-Adipositas_2024-10.pdf

A year ago, on 1 August 2025, Minneapolis added height and weight to the protected classes of its Civil Rights Ordinance. The City Council had approved the amendments unanimously on 1 May, Mayor Jacob Frey approved them on 5 May (Ordinance No. 2025-022), and on the day they took effect the city announced that anyone “living, working or visiting Minneapolis” now had new protections in employment, housing, education, business, professional organisations, public accommodations and public services.

That is worth reporting a year later rather than on the day, because two details only become visible once you read the text next to the city’s own explanation of it. One of them is better than almost anything else on the books. The other is the reason this article exists.

The good part: it protects the impression, not the number

Most legal protection for fat people runs through a diagnosis. You get a claim to the extent that you can be described as impaired, disordered or ill. We have written about that trade in Weight Discrimination: What You Can Actually Do, and it is the central weakness of the disability route.

Minneapolis does not do that. The city’s own protected class page defines the ground plainly: height means how tall you are, weight means how much you weigh, and this “includes actual numbers and how people see you, such as tall or short, heavy or light.”

That second half is the important one, and it is in the ordinance text itself. The definition, as quoted by the law firm Ogletree Deakins from the signed amendment, reads: “A numerical measurement of body height, body weight, or body size. Height encompasses, but is not limited to, an impression of a person as tall or short, regardless of numerical measurement. Weight encompasses, but is not limited to, an impression of a person’s weight (fat, thin, etc.), regardless of numerical measurement.” Employment lawyers reading it point out what follows: future claims may mirror the “regarded as” analysis familiar from the Americans with Disabilities Act and the Minnesota Human Rights Act, which lets someone bring a claim on perceived rather than actual status.

This matters because discrimination does not consult a scale. Nobody is turned down for a job at a BMI cut-off. They are turned down because someone in the room decided they looked lazy, unhealthy, unrepresentative, or “not a fit”. The harm attaches to the attribution, and Minneapolis attached the protection to the attribution as well. Michigan, which has protected weight since 1977, and New York City, which added it in 2023, protect the characteristic. Minneapolis protects being seen as having it.

The part that cancels a good deal of it

The same amendments contain a carve-out. According to employment-law analyses of the signed ordinance, the protections relating to height and weight do not override actions an employer takes to comply with other federal, state or local law, and the ordinance further clarifies that it does not prohibit covered entities from offering voluntary wellness program incentives that promote healthy weight management.

Read those two sentences together. An employer in Minneapolis may not treat you worse because they think you are fat. The same employer may attach money to you becoming less so, as a benefit, on a voluntary basis, with the city’s explicit blessing.

We were not able to open the signed ordinance PDF at the city’s legislative document server; it is behind a bot check that blocks direct retrieval. So this clause is reported here on the authority of two independent law-firm analyses of that document, published three weeks apart and each linking to it: Stinson LLP writes that the ordinance “further clarifies that it does not prohibit covered entities from offering voluntary wellness program incentives that promote healthy weight management”, and Saul Ewing writes that “the ordinance makes clear that employers are permitted to offer incentives supporting weight management as part of a voluntary program without violating the law.” What we can verify directly is the other half of the point: the city’s public-facing protected class page, the page an ordinary resident would read to find out what the law now does for them, lists the exceptions for essential job duties, undue hardship and direct threat. It does not mention the wellness carve-out at all.

Why this is not a technicality

An anti-discrimination ground says something specific: this characteristic is not a legitimate basis for treating people differently, and it is not something people can or should be asked to change. That is the definition Minneapolis itself uses. A workplace incentive for “healthy weight management” says the opposite, in the same building, from the same employer, with money attached.

The two messages do not cancel out neatly. The employer who runs the incentive scheme is the employer who later decides whether you are “a fit”. Voluntary is doing a lot of work in that sentence, and it is doing it in a room where one party sets the salary.

There is a defensible reason for the exception, and it is not hidden: employers in the United States operate wellness programmes under a thicket of federal rules, and a city ordinance that made them unlawful would put employers in conflict with law they cannot opt out of. The ordinance says as much in its own compliance clause. That explains the carve-out. It does not make the contradiction go away. It relocates it: the city has protected the ground as far as city law reaches, and the incentive structure sits in the part it does not reach.

What Minneapolis actually gets you, and where it stops

Height and weight can still be considered where a person cannot be accommodated without changing the main purpose of a programme or service, or where health or safety would be at risk. Employers additionally have a defence where height or weight prevents someone from performing essential job duties, where accommodation would be an undue hardship, or where there is a direct threat to health or safety. Those are conventional limits and they are the same ones disability law uses.

The reach is the notable part. Minneapolis covers employment, housing, education, business, professional organisations, public accommodations and public service, and applies to any employer with an employee performing services in the city, wherever the employer sits. With this, Minneapolis joins Michigan, New York City, Washington DC, San Francisco, Santa Cruz, Madison, Urbana and Binghamton on a short list.

The German question this raises early

Germany has no weight ground at all. The General Equal Treatment Act (AGG) does not list body weight, and fat people in Germany argue through disability, general civil law, or nothing. A parliamentary motion to add body weight, among other characteristics, had its first reading in the Bundestag in June 2026 (Drucksache 21/4538, tabled by the opposition group Die Linke). It is a proposal, not law, and we covered it when it was introduced.

Here is what Minneapolis makes worth asking now rather than later. Germany does not have to invent an employer weight-incentive structure; it already has one, in statute. Under Section 20b of the Fifth Book of the Social Code, the statutory health insurers fund workplace health promotion, specifically the building of health-promoting structures inside firms. Section 65a governs bonuses for health-conscious behaviour, and its second paragraph reads: the health insurer “should also provide in its bylaws that, for workplace health promotion measures run by employers, both the employer and the participating insured persons receive a bonus.”

Whether any given programme targets weight is a matter of programme design, not of the statute, and we are not claiming the statute mandates it. The point is structural. If body weight became a protected characteristic in the AGG, it would land on top of a subsidised, legally anchored system of employer-side health incentives that nobody has yet had to test against a weight ground, because there is no weight ground to test it against. Minneapolis had to answer that question and answered it with an exception. Germany would have to answer it too, and the time to ask is while the text is still being drafted.

If you are dealing with this now

• Know which door you are using. In most places the weight ground does not exist and the argument runs through disability. What that costs you is set out in our cornerstone on weight discrimination.
• Separate the offer from the assessment. A wellness incentive is not evidence of discrimination. Being passed over afterwards, by the people who ran it, may be. Keep the two records separately and keep them dated.
• Medical settings are a different fight. See What to Do When a Doctor Blames Everything on Your Weight and How to Find a Weight-Neutral Doctor.

A law that bans discrimination on the basis of being seen as fat, and in the next clause protects the programme that pays you to stop being fat, is not a failure. It is a good law with the shape of the problem still visible in it. That shape is worth naming before the next jurisdiction copies the text.

---

Sources: City of Minneapolis, “Minneapolis expands anti-discrimination protections in Civil Rights Ordinance”, 1 August 2025, https://www.minneapolismn.gov/news/2025/august/new-civil-rights-protections · City of Minneapolis Department of Civil Rights, “Protected classes”, retrieved 15 August 2026, https://www.minneapolismn.gov/government/departments/civil-rights/complaint-investigations/protected-class · Stinson LLP, “Minneapolis Amends Its Civil Rights Ordinance to Expand Protections in Employment Decisions”, 16 June 2025, https://www.stinson.com/newsroom-publications-minneapolis-amends-its-civil-rights-ordinance-to-expand-protections-in-employment-decisions · Saul Ewing LLP, “Minneapolis Expands Anti-discrimination Ordinance”, 12 June 2025, https://www.saul.com/insights/blog/minneapolis-expands-anti-discrimination-ordinance · Ogletree Deakins, “Local Politics Makes a Big Splash”, 17 June 2025 (quoting the ordinance definitions), https://ogletree.com/insights-resources/blog-posts/local-politics-makes-a-big-splash-amendments-to-minneapolis-civil-rights-ordinance-provide-further-protection/ · Jackson Lewis P.C., “Minneapolis Anti-Discrimination Law Revised”, 22 May 2025 · Signed ordinance No. 2025-022, City of Minneapolis legislative information system, document 39068 (linked by all four firms; not directly retrievable, the server returns a bot challenge) · Elliott-Larsen Civil Rights Act, Act 453 of 1976 · NYC Local Law 61 of 2023 · Deutscher Bundestag, Drucksache 21/4538, first reading June 2026 · SGB V § 20b and § 65a, https://dejure.org/gesetze/SGB_V/65a.html

A randomized experiment with 1,313 participants tested how people judge someone who lost weight on a GLP-1, someone who lost it by dieting, and someone who didn’t lose any. The drug user came out worst. Here is what the study shows, and where its numbers are thinner than the headlines.

There is a promise buried inside every weight-loss conversation: do this, and people will stop treating you that way. A study published in the International Journal of Obesity on 3 April 2026 put that promise into an experiment, and the promise did not survive.

Erin Standen (Rice University), Sean Phelan (Mayo Clinic) and Janet Tomiyama (UCLA) ran two randomized, between-subjects experiments. Participants read a short description of a fictional person and then rated them. The only thing that changed between groups was how that person’s weight history was described.

What the participants actually read

In both studies the fictional target was the same person: 38 years old, college-educated, gender deliberately left unspecified, described as having had obesity since puberty, currently around 220 pounds (roughly 100 kg). The authors say they built these details around an average-aged, average-weight U.S. adult with the most common age of onset.

Study 1 (N = 607, recruited on Prolific in October 2024) split participants into three groups. The target had either lost 35 pounds (about 16 kg) over the past year using a GLP-1 medication, lost the same 35 pounds through diet and exercise, or had not lost weight at all. In both weight-loss conditions the description added that the person was no longer in the “obese” BMI category.

Study 2 (N = 706, February 2025, no overlap with Study 1) had four groups: regained the weight after stopping a GLP-1, regained it after stopping a diet-and-exercise plan, never lost weight, or lost weight and kept it off with the method unspecified.

Participants then rated the person on ten positive traits (honest, generous, sociable, productive, organized, friendly, outgoing, intelligent, warm, humorous) and eight negative ones (lazy, undisciplined, self-indulgent, unclean, weak-willed, sloppy, insecure, sluggish) on a 1-to-7 scale, rated them separately on “unhealthy”, and answered six questions about whether they would want anything to do with them, adapted from the Interpersonal Attraction Questionnaire. The study materials and the de-identified data are public on OSF.

What they found

Against the diet-and-exercise version of the same person, the GLP-1 version lost on every measure: fewer positive traits, more negative traits, rated more unhealthy, and less socially wanted (all Tukey HSD p < 0.001).

Then came the finding that made the press releases. The authors had predicted that the person who did not lose weight would be judged most harshly of all. That is not what happened. Compared to the GLP-1 user, the person who never lost weight was rated higher in positive traits (p = 0.003), and people were more willing to spend time with them. On willingness to affiliate, all three groups differed from each other: diet and exercise 5.51, no weight loss 5.25, GLP-1 4.99, on a seven-point scale (F(2, 603) = 12.54, p < 0.001).

In plain terms: in this experiment, taking the drug cost more social standing than staying fat.

Where the numbers are thinner than the headline

Two things get lost when this study is summarized in a sentence, and both matter.

First, the “worse than not losing weight at all” result is narrower than it sounds. It holds for positive traits and for willingness to affiliate. It does not hold for the negative traits, and it does not hold for “unhealthy”: on both of those, the GLP-1 user and the person who never lost weight were rated the same (p = 0.26 for each). So people did not call the drug user lazier or unhealthier than a fat person who did nothing. They just liked them less and granted them fewer good qualities.

Second, the effects are small. The gap in willingness to affiliate between the GLP-1 user and the person who never lost weight was 0.26 points on a 1-to-7 scale, with a confidence interval running from 0.02 to 0.51 — that is, just barely clear of zero. The effect size for the whole model was ηp² = 0.04 in Study 1 and 0.01 in Study 2. These are real, statistically significant differences, and they are not large ones.

Third, and this is a limitation the authors state themselves: participants were rating a paragraph about a person who does not exist. That design buys clean causal inference and pays for it with artificiality. All participants were U.S. adults recruited on an online survey platform. Nothing here has been shown for Germany, and nothing here has been measured on actual behaviour towards actual people.

The part nobody quoted

Study 2 is the more interesting half, and it got almost no coverage.

When the weight came back, the difference between the drug and the diet disappeared entirely. Participants rated the person who regained after a GLP-1 and the person who regained after dieting the same way — no difference in positive traits, negative traits or unhealthiness (p > 0.55). What did produce a large difference was regain itself: both regain groups were rated significantly higher in negative traits and more unhealthy than the person who lost weight and kept it off (p < 0.001).

So the “easy way out” penalty is attached to the ongoing state of having taken a shortcut. Once you are fat again, nobody cares how you briefly stopped being fat. You are simply back to being blamed for the weight.

Two words we are not going to use

The Rice press release calls this “the GLP-1 paradox”. The paper does not use the word “paradox” once. It is a framing added afterwards, and it is the wrong frame, because it implies something contradictory happened. Nothing contradictory happened.

Look at what the trait list is actually measuring: lazy, undisciplined, self-indulgent, weak-willed. That is not a list of things people believe about fat bodies. It is a list of things people believe about fat character. The judgement was never really about the number on the scale. It was about whether you are the kind of person who takes the hard road. A drug removes the weight without removing that suspicion — it confirms it. Which is exactly why the diet-and-exercise version of the same person, with the same body, scored best of all three.

There is no paradox in a moral system that rewards suffering. There is only consistency.

What follows from it

We have written before about how the injection moves the shame rather than dissolving it, and about how access to these drugs splits along class lines. This study adds the piece that was missing: a direct comparison with the option of not losing weight at all. And on the measures where it holds, that option came out ahead.

This is not an argument for or against anyone’s medication. It is nobody’s business what you put in your body, and the authors’ own conclusion is that stigma reduction, not behaviour change, is the thing that needs work. It is an argument against the promise. If you are being told that the judgement stops once the weight does, the best available experimental evidence says otherwise. It does not stop. It re-attaches.

Which means the thing worth working on was never the body. It is the standard being applied to it.

---

Sources

• Standen EC, Phelan SM, Tomiyama AJ. An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation. International Journal of Obesity 50, 1478–1485 (2026), published 3 April 2026, open access. https://www.nature.com/articles/s41366-026-02061-y
• Study materials and de-identified data: https://doi.org/10.17605/OSF.IO/7FM2R
• Rice University press release, 4 May 2026: https://news.rice.edu/news/2026/glp-1-paradox-rice-study-finds-weight-loss-drugs-may-carry-unexpected-stigma

A note on language: the paper uses “higher-weight” and BMI categories throughout, and treats weight loss as a health goal. We quote its findings, not its framing.

In eight days, the largest documented gathering of fat people in Germany takes place in Frankfurt am Main. It runs for a weekend, offers around 30 sessions, and the concession ticket costs 15 euros. It is called the Adipositas.Camp, the Obesity Camp.

That is good news first. The place exists, it is cheap, it is national, and it treats stigma and weight discrimination as subjects in their own right rather than a footnote. It is also news about the state of the country. If you want to meet other fat people offline in Germany, you have essentially two doors. One is labelled illness. The other is labelled dating. A third one, where fat people are simply a social group, does not exist on a national scale.

What happens in Frankfurt on 22 and 23 August

Adipositas.Camp 2026 runs from Saturday 22 August, 10:00, to Sunday 23 August, 16:00, at Saalbau Titus-Forum, Walter-Möller-Platz 2, 60439 Frankfurt am Main. The organiser is Adipositaschirurgie Selbsthilfe Deutschland e. V., AcSD, which translates as Bariatric Surgery Self-Help Germany.

The announcement describes it as a meeting point for people living with obesity and for leaders of self-help groups from across Germany. Thirty sessions are planned, partly in parallel, organised by the self-help community itself with expert support where it helps. The organiser names three strands: the medical perspective including the practical business of implementing therapies, nutrition and movement; deeper workshops on causes and mechanisms; and, in its own words, for those “interested in society”, the topics of stigmatisation, discrimination and health policy.

Prices as of today:

• full weekend: 29 euros
• weekend for first-time attendees (“Neucamper”): 19 euros
• full Saturday or full Sunday: 19 euros each
• concession weekend ticket: 15 euros, for students and people receiving social benefits, proof required at the door

Registration runs through a form on the event page, it is binding, and places are confirmed in order of payment received while places last.

For scale: a weekend with 30 sessions for 15 to 29 euros is not a normal German conference price. This is volunteer work, not a commercial product.

The name is not an accident, and it is the actual point

AcSD grew out of self-help after bariatric surgery, and the website’s information portal is built accordingly: gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass, gastric balloon, risks, aftercare, social court rulings, clinical guidelines.

That is entirely consistent with this association’s mandate. It also shapes the frame the camp sits in. The camp announcement speaks of “living with the disease”. The first content bullet of the accompanying workshop series on weight discrimination reads “obesity as a disease”, followed by “bringing order to the terminological chaos”.

None of this is a criticism of the association. AcSD does work nobody else does at this scale, and it does more against weight discrimination than most better-funded bodies: there is a dedicated workshop series with role play, communication exercises and concrete options for action, and there are concession tickets so that money is not the barrier.

The question is not what AcSD does. The question is why nothing exists beside it.

Because the frame has consequences. Anyone unwilling or unable to say “I am ill” enters this room carrying a precondition others do not have to carry. For some people that is irrelevant or even useful, because in Germany recognition as a disease triggers concrete things, from reimbursement to being taken seriously in a consulting room. For others it is precisely the label they have spent half their life arguing against. Those people meet nobody offline.

What else exists

We checked rather than asserted. Three things exist. None of them closes the gap.

The Stammtische. On rubensfan.de, a dating site for fat and plus-size people, sits the liveliest fat offline network we could find in Germany. Its forum section for meetups carries a continuous stream of real events with high sequential numbers: the 30th Duisburg meetup on 5 September 2026, the 121st and 123rd in Cologne, the 27th in Mannheim, the 4th in Hamburg, the 10th in the Oberallgäu, the 113th in Lindau, plus a board game meetup in Oberhausen with dates in September, November and December 2026. This is infrastructure grown over years, and it is open to anyone. It is also the by-product of a dating platform whose forum includes a section on losing weight. It is not a place where fat people organise politically, and it does not claim to be.

The queer spaces in Berlin. They exist, and they came first. On 22 January 2019, the Berlin queer magazine SIEGESSÄULE described a whole scene: the Fat Queer Hang Out at the H48 project space in Neukölln, every second Tuesday of the month; the series “Reframe Fat, Reclaim Movement” at xart splitta e. V.; the “Fat Live, Die Yum” dinners; the Fat Cabaret at Ballhaus Berlin. Important caveat: that report is seven years old. We have not verified which of these formats still run in 2026, so we do not claim they do. What is clear is that they were local Berlin offerings, some very small, some tied to individual organisers. If you live in Bremen or Chemnitz, they were never available to you.

The advocacy association. Gesellschaft gegen Gewichtsdiskriminierung e. V. in Berlin, the Society Against Weight Discrimination, is the only German body that treats fat people explicitly as a human rights subject rather than a diagnosis. It campaigns for body weight to be added to section 1 of the General Equal Treatment Act, for lower thresholds allowing small organisations to be recognised as anti-discrimination bodies under section 23, and for one extra seat on the advisory board of the Federal Anti-Discrimination Agency.

The German Bundestag’s lobby register also shows the scale of that counter-voice. For financial year 2023 the entry lists 39 members, all of them natural persons, lobbying expenditure between 1 and 10,000 euros, and 0.00 full-time equivalents assigned to it. The one substantial public grant, 70,001 to 80,000 euros from the Federal Anti-Discrimination Agency’s respekt*land programme, was earmarked for developing a training course that qualifies anti-discrimination counselling centres on weight discrimination. Since 24 October 2025 the register lists the association as a former interest representative. We do not know what that means internally and make no claim about it; in the register it no longer appears as an active interest representative.

One of this association’s offerings is the closest thing currently available to readers of this piece: a free monthly online talk that serves as a preview of the training course. One documented instance is 23 January 2025, 18:00 to 20:00, “Well treated? Weight discrimination in medicine”, free of charge, registration by email to fortbildung@gewichtsdiskriminierung.de. The remarkable part is the last line of the announcement: after the talk, the room stays open for another half hour, explicitly for fat people who want to network. That half hour is, in Germany, what in the United States is an organisation with committees and an annual programme. We could not verify today whether and when the series currently runs, because the website would not load for us. The training address above is how to ask.

The gap, in numbers

Based on this research, Germany has no national, weight-neutral gathering of fat people that is neither medically framed nor built around dating. What it has is a volunteer association from bariatric surgery with 30 sessions and concession tickets, a dating forum with a hundred and fifty pages of meetup history, a Berlin scene of unclear current status, and an advocacy body with 39 members and zero staff.

That explains a good deal about why German debate on fat bodies runs so reliably along medical lines. No rooms means no spokespeople. No spokespeople means professional societies speak for you. And professional societies talk about patients.

If you want to go

The camp is eight days away. What we saw at the source today, 14 August 2026:

• Adipositas.Camp 2026, 22 August 10:00 to 23 August 16:00, Saalbau Titus-Forum, Walter-Möller-Platz 2, 60439 Frankfurt am Main. 15 to 29 euros, registration form on the event page.
• 26th Adipositastag, 31 October 2026, 10:00 to 18:00, Frankfurt and online. Programme still listed as to be announced. On-site tickets between 7.50 euros for first-time attendees and 24 euros for the VIP category, online between 7.50 and 24 euros.
• “Weight discrimination, no thanks! … on Tour”, the workshop series. Regional small-group workshops are announced for Berlin, Bremen, Cologne, Leipzig, Nuremberg and Saarbrücken, from September according to the website, Saturdays 10:00 to 16:00, 29 euros per date, 15 euros concession, 39 euros for a combined ticket with the masterclass.

And now the awkward part, which we are not going to hide: the dates for that series are not internally consistent on the website. The booking form names specific days for two cities, 13 September for Bremen and 27 September for Saarbrücken, both without a year. In 2026 both dates fall on a Sunday, while the text explicitly announces Saturdays. In 2025 both were Saturdays, and the campaign graphic on the same page is stored as a 2025 file. Likewise, the body text puts the masterclass on “Sunday 10 May”, while the same association’s own event calendar puts it on 1 November 2026.

Our conclusion, stated openly: reliably datable for 2026 are the camp on 22 and 23 August, the Adipositastag on 31 October and the masterclass on 1 November. We would confirm the regional workshop dates by phone or email before booking any travel. This is not negligence anyone should hold against the association. It is the ordinary result of a volunteer structure maintaining a website that other organisations staff with employees.

Finally

Nothing in this piece is about whether anyone should weigh less. It is about the fact that a country of 83 million people has exactly one national weekend where fat people can meet each other, and that the ticket in runs through the language of illness. Those who can accept that language will find a cheap, sincere, volunteer-built offering. Those who cannot currently find nothing comparable in Germany. If you are looking for a weight-neutral doctor in the meantime, we have a guide for that.

This article is not medical advice and not a recommendation for or against any treatment. It describes events and the frame around them.

Sources

All dates and prices verified at the source on 14 August 2026.

• AcSD e. V., events calendar: acsdev.de/calendar
• AcSD e. V., Adipositas Camp 2026: acsdev.de/Veranstaltung/ac2026
• rubensfan.de, meetups forum: rubensfan.de
• SIEGESSÄULE, “Fett-Aktivismus in Berlin”, 22 January 2019: siegessaeule.de
• Lobby register of the German Bundestag, entry R007584: lobbyregister.bundestag.de
• Antidiskriminierungsbüro Sachsen e. V., event listing, 23 January 2025: adb-sachsen.de

Before we start: this article is not about whether retatrutide works, and it is not a recommendation for or against any drug. It is about a question that comes before that one. Who decides who is allowed to stand at the front of a line that does not officially exist yet?

What happened

On 3 August 2026, Eli Lilly confirmed that a defined group of patients can apply for early access to retatrutide, an obesity drug that has not been approved by the US Food and Drug Administration. A company spokesperson told Reuters that for “a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial,” Lilly considers it “medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA’s guidance.” The company said it had built an expanded access programme and was “actively reviewing requests from health care providers.”

The announcement did not arrive on its own. It arrived after four months of pressure, and the pressure started with one patient.

In April, Lilly granted a single 79-year-old patient compassionate-use access to retatrutide, months before any broader framework existed. STAT News first reported the case in June. According to that reporting, the application was filed by a senior clinician at the National Institutes of Health and cited refractory obesity, obstructive sleep apnoea and pulmonary hypertension.

Then it turned political. STAT asked the White House whether the recipient was President Donald Trump, who turned 80 in June. A spokesperson said the application was not for the president. Democratic lawmakers have since pressed the administration for more detail about who the recipient was. As of the reporting we could verify, the identity has not been disclosed.

Meanwhile, doctors who had asked the same company for the same thing on behalf of their own patients described weeks of silence. Spencer Nadolsky and Mike Albert, both of the online obesity clinic Vineyard, told STAT they had applied for several patients who had not responded adequately to Lilly’s approved drug Zepbound. Nadolsky said one of his patients received only a preliminary qualification, and only after STAT contacted Lilly for comment. Angela Fitch, chief medical officer of the obesity clinic knownwell, said clinicians “are owed an explanation of some sort” about whether a formal programme existed at all.

So the sequence reads: one person gets in, a news organisation asks about it, lawmakers ask about it, and then a programme appears.

The criteria, and the fact that they come in two versions

Here is what a patient now has to satisfy. Be 18 or older. Have refractory obesity. Have two or more serious or life-threatening obesity-related complications for which they are currently receiving standard care. Be unable to enrol in a trial of retatrutide or a comparable investigational medicine. Have discussed all standard treatment options, including bariatric surgery.

That is already a narrow door. But there is a detail worth sitting with, because it is the kind of thing that decides individual cases and almost never makes headlines: the criteria exist in two slightly different published versions.

A source familiar with the programme told STAT that patients must be 18 or older, unable to join a trial, have refractory obesity with two or more serious complications, and have discussed all standard options. Reuters, quoting a company spokesperson, reported something stricter: refractory obesity despite tolerating the highest approved dose of an obesity therapy. The American Journal of Managed Care, which laid the two accounts side by side on 5 August, put it plainly: depending on the account, the requirement is either maximum-dose treatment failure or documented discussion of standard options. The discrepancy had not been reconciled at the time of publication.

Two versions of a rule is not a footnote. It is the difference between a patient who qualifies and a patient who does not, and neither the patient nor their doctor gets to see the version that will be applied to them. Fitch said she had not submitted an application yet and was still trying to find out from Lilly whether patients would even need to travel to a clinical trial site to receive treatment.

Not every specialist wants in. Fatima Cody Stanford of Harvard Medical School and Gitanjali Srivastava of Vanderbilt University Medical Center told STAT they are not pursuing compassionate use for their patients and want more safety data before offering the drug outside a monitored trial. Stanford, herself a clinical investigator on Lilly’s retatrutide trials, said she does not believe the company intended to extend access beyond the original patient, and now has to manage a programme it may not have planned to build.

Who actually holds the key

The instinct is to blame the regulator. That instinct is wrong here, and the correction matters, because it points at where the power actually sits.

The FDA’s own guidance for physicians describes expanded access as a pathway with three roles. The patient consults a physician. The physician agrees to oversee treatment, files the paperwork with the FDA and an institutional review board, and takes responsibility for care and reporting. And the company has to be “willing to provide the investigational medical product.” The FDA states that it authorises the vast majority of expanded access requests it receives. What it cannot do is order a manufacturer to hand over a drug it does not want to hand over.

So the bottleneck is not a government office. It is a corporate decision, and there is no external standard the decision has to meet, no published queue, and no appeal.

That is the part worth carrying out of this story. For a drug that has not been approved, there is no right of access anywhere in this system. There is only a company’s willingness, and willingness is distributed by whoever happens to have reach: a senior clinician at a federal research institution, a reporter with a phone number, a member of Congress with a letterhead.

Would Germany handle this differently? Partly

German law has a version of the same pathway, and it is stricter in ways that are easy to miss.

Under § 21 (2) no. 3 of the Arzneimittelgesetz, a medicine needs no marketing authorisation if it is supplied free of charge, under the conditions of Article 83 of Regulation (EC) 726/2004, to patients with a seriously debilitating or life-threatening illness who cannot be satisfactorily treated with an authorised medicine. (Older guidance documents, including the page the federal regulator BfArM still publishes, cite this as no. 6, from the earlier numbering. The current statute reads no. 3.)

The procedure sits in a separate ordinance, the Arzneimittel-Härtefall-Verordnung, in force since 22 July 2010. Under § 3, whoever initiates, organises and finances such a programme has to notify the competent federal authority and file a defined set of documents. Under § 4, the authority confirms receipt within two weeks, the programme may only begin once that confirmation has arrived and the authority has not objected, and the authority may object if the conditions are not met.

Compare that with what happened in the US case. In Germany, a group programme cannot quietly exist or quietly not exist. It has to be declared to a public authority, it cannot be sold, and a public body can stop it.

But here is the limit, and it is stated on BfArM’s own page: the ordinance applies only to programmes intended for groups of patients. Treatment of an individual single case is explicitly not covered by the ordinance or its notification procedure.

Which means the exact thing that started this story, one named-nowhere person receiving an unapproved drug ahead of everyone else, would fall outside the visible procedure in Germany too. The German system makes programmes accountable. It does not make individual favours visible. And in both countries, the company still decides whether to run a programme at all.

Why this belongs in a magazine about fat people

Because it is the same shape as everything else we have documented this year, and the shape is starting to be the story.

In France, weight-loss drugs are reimbursed; in Germany the law files them under lifestyle. In the US, access to GLP-1 drugs already splits along income lines, and the split punishes twice. Germany’s own reimbursement debate, as we described when the G-BA leadership questioned the exclusion, offers coverage at the price of being classified as ill. And in law, body weight is not a protected characteristic in the US, the UK or Germany; protection runs through disability law, which means through a diagnosis.

Every one of those is the same trade. Access is available, but only in exchange for a category: sick enough, poor enough, diagnosed enough, connected enough. What the retatrutide case adds is the crudest version: access in exchange for proximity to power.

There is a second reason. When the evidence about these drugs arrives, it mostly arrives from the people selling them. Three Cochrane reviews of tirzepatide, semaglutide and liraglutide, reported by Deutsches Ärzteblatt on 7 November 2025, found clinically meaningful weight reduction for as long as treatment continues, and all three research teams pointed out emphatically that most of the underlying randomised trials were manufacturer-funded. We wrote about who pays for the studies that shape this debate earlier this month. It applies here too.

For the record, the numbers Lilly is building its approval case on come from the company’s own announcement of 23 July 2026: in TRIUMPH-2, adults with type 2 diabetes and obesity or overweight lost up to an average of 20.8 per cent of body weight at 80 weeks on the highest dose; in TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to an average of 22.6 per cent. Lilly plans to file for approval with the FDA in the first quarter of 2027. We report those figures as what they are: topline results announced by the manufacturer, not an independent verdict, and not a reason for anyone to want or not want a drug.

The thing to take away

A 79-year-old man got a medicine that officially does not exist yet. We do not know who he is. His doctors at a federal research institute knew how to ask. Other doctors asked and waited weeks. Then journalists asked, and lawmakers asked, and a programme appeared with rules that come in two versions.

Nothing about that is an argument about bodies. It is an argument about queues, and about who is allowed to write the rules for standing in them. For fat people, who spend a great deal of time being told that their health outcomes are a matter of personal effort, it is worth naming out loud how much of the actual access in this system is decided by proximity, paperwork and press attention.

Sources

• Sneha S K, Deena Beasley: Eli Lilly to offer early access to next-gen obesity drug to some patients. Reuters, 3 August 2026. https://www.reuters.com/legal/litigation/eli-lilly-offer-early-access-next-gen-obesity-drug-some-patients-2026-08-03/
• Lizzy Lawrence, Elaine Chen: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug. STAT, 3 August 2026 (STAT Plus, full text behind paywall; details used here are as reproduced by AJMC and Reuters). https://www.statnews.com/2026/08/03/eli-lilly-retatrutide-mystery-patient-doctors-seek-same-access-their-patients/
• Giuliana Grossi: Lilly Expands Retatrutide Access Amid Doctor Pushback. The American Journal of Managed Care, 5 August 2026. https://www.ajmc.com/view/lilly-expands-retatrutide-access-amid-doctor-pushback
• Eli Lilly and Company: Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. News release, 23 July 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
• US Food and Drug Administration: Expanded Access, Information for Physicians. https://www.fda.gov/news-events/expanded-access/expanded-access-information-physicians
• § 21 Abs. 2 Nr. 3 Arzneimittelgesetz. https://www.gesetze-im-internet.de/amg_1976/__21.html
• §§ 1, 3, 4 Arzneimittel-Härtefall-Verordnung. https://www.gesetze-im-internet.de/amhv/
• BfArM: Arzneimittel-Härtefallprogramme / Compassionate Use. https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Compassionate-Use/_artikel.html
• Fast alle Studien zu Abnehmspritzen von Herstellern finanziert. Deutsches Ärzteblatt, 7 November 2025 (Cochrane Database of Systematic Reviews 2025, DOI 10.1002/14651858.CD016018, 10.1002/14651858.CD015092.pub2, 10.1002/14651858.CD016017). https://www.aerzteblatt.de/news/fast-alle-studien-zu-abnehmspritzen-von-herstellern-finanziert-a4c0435a-b30e-4d18-92f3-4ccdf5087d1c

Note on sourcing: The STAT article is behind a paywall. Every detail attributed to STAT in this piece is taken from AJMC’s fact-checked summary of it or from Reuters, both of which cite STAT explicitly. No quotation is reproduced here that we could not find in an accessible source. The identity of the April patient is not known and is not speculated about here beyond the White House denial that has been reported.

The new chair of Germany’s most powerful health body has said something nobody in that chair has said before. She also named, quite precisely, what it would cost.

Sonja Optendrenk has led the Gemeinsamer Bundesausschuss (G-BA) since early July 2026. The G-BA is the joint self-governing body that decides which treatments the statutory health insurers reimburse for 74 million insured people in Germany. In early August she told the news magazine Der Spiegel that it would be worth considering recognising weight-loss drugs as a reimbursable benefit under certain conditions. In her words, as reproduced by the dts news agency and by Tagesspiegel: Germany is having “a backward discussion about obesity”. Other countries, she said, notably the United Kingdom, have “consistently accepted that this is a real illness that cannot be reversed by sport and better nutrition alone”.

This is a proposal, not a decision. But it comes from the office that would have to write the details, and it is more specific than such proposals usually are.

What the statute actually says

The reason Wegovy and Mounjaro are paid for out of pocket in Germany sits in section 34, paragraph 1 of the Fifth Social Code. It excludes medicines whose use primarily serves “an increase in quality of life”. Then comes a list worth reading in full. Excluded in particular are medicines predominantly used:

• to treat erectile dysfunction
• to stimulate or increase sexual potency
• for smoking cessation
• for slimming or appetite suppression
• to regulate body weight
• to improve hair growth

That is the company fat bodies keep in German social law: filed between potency drugs and hair growth. Not as an accident of drafting, but as the law in force.

Optendrenk points at exactly that. The fact that drugs explicitly licensed to treat obesity fall under this paragraph is, for the people affected, “a sign that this recognition is missing”.

It is the most honest description of the problem to come from that direction so far. The issue is not only money. It is which list a body gets sorted into.

The precedent is sitting in the same section

What separates this from a statement of intent is that the template already exists one paragraph down.

For smoking cessation, the legislature has already broken its own rule. Section 34, paragraph 2 gives insured people with a diagnosed severe tobacco dependence a claim to a one-time supply of cessation medication, but only within evidence-based programmes. A repeat supply is possible no earlier than three years after the first course ends. And the specifics, which drugs under which conditions, are set by the G-BA in its own guidelines.

So smoking cessation remains on the exclusion list in paragraph 1 and still has a narrow, conditional claim in paragraph 2. The legislature cuts the exception, the committee fills it in.

That is precisely the mechanism Optendrenk floated: the legislature could instruct the G-BA to determine which patient groups should receive the drugs, for how long, and with what accompanying measures. Anyone wanting to know what that looks like in practice does not have to speculate. The tobacco rule is the blueprint: a certified severity, a programme around it, a waiting period.

The price is written into the same sentence

This is where it gets complicated for fat people rather than simply good.

In Optendrenk’s own argument, the route to coverage runs through recognition as a disease. The UK, she says, accepted that this is a real illness. Access follows once the body counts as requiring treatment.

That is the same logic German guideline medicine runs on. The national obesity guideline added a dedicated chapter on stigmatisation in 2024, and that chapter closes by arguing that recognising obesity as a disease implies making billable treatment available nationwide. Destigmatisation as the argument for more treatment. We set out the fault line in our guide to what Health at Every Size actually means: one framework says care should not have to be earned, the other says care arrives once the body carries a diagnosis.

Both beat the status quo, in which fat people are neither recognised nor treated. But they are two different futures. In one you get care because you are a person. In the other you get it because you are a case.

Her own caveat is the most interesting part

Optendrenk limited her own proposal, and more sharply than the headlines suggest: “As long as the weight comes straight back after stopping, an injection alone is not a model of care.” Long-term studies, she noted, are missing.

That sentence can be read two ways, and both readings will be used in the coming months.

Read weight-neutrally, it says: a drug whose effect ends when you stop taking it is no substitute for care that takes fat people seriously. That matches what the research already shows, and it argues against the idea that a prescription settles the matter.

Read from the industry side, the same sentence says: if the weight comes back after stopping, then nobody should stop. A time-limited treatment becomes permanent medication, and a line item becomes a subscription. Anyone who has followed the American coverage fights knows this argument. We traced the access question across countries in France pays, Germany does not and the class dimension in the GLP-1 access gap.

Which reading wins will not be decided by her sentence. It will be decided by whoever gets to define the accompanying measures she mentioned.

What it means in practice

In the short term, nothing. There is no decision, no instruction from the legislature and no timetable. Anyone who wants a prescription today still pays for it themselves.

Over the medium term, three things are worth watching, because they decide whether a change creates access or builds a new hurdle.

The eligibility criteria. Following the tobacco model, some certified severity will be required. For weight that almost certainly means BMI thresholds. Anyone just below falls out, and the line is always arbitrary.

The accompanying measures. Mandatory programmes can mean good care, or they can mean a compliance test in which reimbursement is tied to demonstrated good behaviour. The difference lives in the detail, and the detail will not be in the statute. It will be in a guideline.

The side effect on everything else. Coverage coupled to disease recognition reinforces the picture of the fat body as a case for treatment. In the very same practice where it opens access to one drug, it can narrow access to everything else. What that looks like in the room is in our guide to what to do when a doctor blames everything on your weight.

What we are not doing here

We are not recommending weight-loss drugs and we are not warning anyone off them. That is a medical decision between you and a practice that takes you seriously.

The point is a different one. A country that files fat bodies next to hair-growth products in its statute book is, for the first time, hearing from the top of its own health self-government that the sentence might be wrong. That is good news. It just arrives with an invoice, and the invoice reads: diagnosis.

The cost argument is already being staged, incidentally. Tagesspiegel puts the direct medical costs of obesity and its sequelae in Germany at roughly 29 billion euros a year, citing current calculations without naming them. We report the figure as what it is: a number circulating in the debate whose source we have not checked against the original. Why that is a recurring problem with numbers about fat people is the longer story in who pays for weight stigma research.

Fatosphere holds one red line: we do not promote diet or weight-loss products, and we do not publish before-and-after logic. This piece reports a health policy debate without recommending any treatment.

Sources

• Sonja Optendrenk interviewed by Der Spiegel, reproduced by the dts news agency (Presse Augsburg, 2 August 2026) and by Tagesspiegel (2 August 2026). The interview itself is paywalled; the quoted sentences match across both reproductions.
• Section 34 of the German Social Code Book V, paragraph 1 (exclusion of medicines primarily serving an increase in quality of life) and paragraph 2 (claim in cases of severe tobacco dependence), read on 5 August 2026 at gesetze-im-internet.de.
• Deutsche Adipositas-Gesellschaft (lead), S3 guideline Prävention und Therapie der Adipositas, AWMF register number 050-001, version 5.0, 7 October 2024, chapter 2 on stigmatisation.

Image credit: cover graphic by Fatosphere, generated programmatically. Not a photograph and not a depiction of real people.

Since 15 June 2026, France’s statutory health insurance reimburses Wegovy and Mounjaro at 65 percent. Germany lists the same two products, by name, as lifestyle drugs, in the same legal category as products for hair growth and erectile dysfunction. Same continent, same molecules, opposite answer.

This article is not an argument that anyone should take these drugs, and it is not a recommendation to lose weight. Fatosphere does not do either. It is about something else: two European states looking at identical evidence and deciding, in opposite directions, whether care for fat people is medicine or a matter of personal taste. And about the fact that both systems, in different ways, make fat people justify themselves first.

Update, 9 September 2026. This piece has been online since 1 August 2026. It now carries a dated section that sets out the German rule line by line, with a source and a date checked for each, including the Wegovy tablet approved in the EU in July 2026 and the 2 August 2026 intervention by the new chair of the Federal Joint Committee. Jump to it: Where German coverage stands.

What France decided

Two ministerial orders published in the French Journal officiel on 28 May 2026 added Wegovy (semaglutide) and Mounjaro (tirzepatide) to the list of reimbursable medicines. Reimbursement started on 15 June 2026 at 65 percent, meaning a patient share of 35 percent, with full coverage possible depending on individual status, long-term illness (ALD) recognition and supplementary insurance.

The conditions are narrow. The French government’s own citizen information service describes the eligible group as people who would qualify for bariatric surgery: a BMI of 40 or higher without a weight-related comorbidity, or 35 or higher with at least one. The drugs count as second-line treatment, permitted only after a documented failure of nutritional management, which the same page defines as less than 5 percent weight loss after six months. They must be prescribed alongside a hypocaloric diet and increased physical activity.

Who may prescribe is restricted too. According to the French health insurance service Assurance Maladie, the first prescription that triggers reimbursement is reserved for specialists working in obesity care: specialised obesity centres, university hospitals, certain rehabilitation and nutrition units, or endocrinologists working with such a centre. Renewals can then come from a general practitioner. An accompanying form has to be filled in once by an authorised doctor, given to the patient and handed to the pharmacist at every dispensing. People who were already buying these drugs privately before 15 June need that form as well if they want their prescriptions reimbursed.

What Germany decided

Germany did not reject reimbursement after weighing the evidence. It never got that far, because the question was settled in 2004.

Section 34 of the German Social Code, Book V, excludes from statutory coverage all medicines whose use is primarily about increasing quality of life. The statute then names its own examples. In the original German wording, the excluded categories are drugs used mainly for erectile dysfunction, for arousal and increasing sexual potency, for smoking cessation, for slimming or curbing the appetite, for regulating body weight, or for improving hair growth (our translation). Body weight sits in that list, in that sentence, next to hair.

On 21 March 2024 the Federal Joint Committee, the G-BA, formally added Wegovy to Annex II of its medicines directive, the annex headed “lifestyle drugs”. Its own press release is unusually candid about how little room it had. During the consultation the committee considered demands for an exception at least for people with a BMI above 30 and weight-related conditions, and concluded that it had no discretion to grant one. The same release notes a consequence that is easy to miss: because the exclusion attaches to the approved indication, Wegovy also cannot be included in Germany’s structured treatment programme for obesity, the DMP Adipositas, which the G-BA had just adopted. The state runs a structured disease management programme for the condition and is legally barred from putting the drug into it.

Mounjaro followed on 19 September 2024. The committee’s own note on that decision states the reasoning plainly: classification as a lifestyle drug is not defined by the disease value of the underlying indication. It follows instead from the match between the approved use, weight reduction, and the examples written into the statute. The committee cites a 2012 Federal Social Court ruling (B 6 KA 50/11 R) for the proposition that it has no discretion here, and calls its own listing merely declaratory.

Read that again, because it is the whole point. Germany’s health authority is not saying that fatness is not a medical matter. It is saying that the question does not arise. The label says weight regulation, the statute says weight regulation, and everything else, including whether the person in front of you is ill, is legally irrelevant.

One molecule, two names, two answers

Semaglutide is sold in Germany as Wegovy, Ozempic and Rybelsus. Ozempic and Rybelsus are approved for type 2 diabetes and have been reimbursable since they entered the market. Wegovy is the same active substance, approved for weight regulation, and is not reimbursable. Tirzepatide works the same way: excluded under the Mounjaro weight-regulation indication, still a statutory benefit for type 2 diabetes.

The chemistry does not change at the pharmacy counter. What changes is which sentence on the marketing authorisation the insurer reads. A body that has already developed diabetes gets treatment paid for. The same body one diagnosis earlier does not.

Both systems make you prove something first

It would be easy to read this as France good, Germany bad. It is not that simple, and the French rule deserves the same scrutiny.

To qualify in France you must first have failed. Not failed in a vague sense: the criterion is a documented course of nutritional management that produced less than 5 percent weight loss in six months. Dieting is not merely permitted alongside the drug, it is the entry ticket, and the drug is only unlocked once the diet has demonstrably not worked. The state has written the logic of diet culture into a reimbursement rule and given it a form number. Then it requires the diet to continue anyway, since the prescription is only valid alongside a hypocaloric regime and increased physical activity.

Germany’s version of prove it is shorter and blunter. There is nothing to prove, because the category has already been decided. If you want the drug you pay for it yourself, and if you cannot, that is treated as a private matter about quality of life.

Both are moral tests. One asks you to document that you tried hard enough. The other tells you the whole area is your own business. Neither starts from the question a health system is supposed to ask, which is what this particular person actually needs.

The contradiction Germany has not resolved

Germany’s own institutions do not agree with each other.

Bariatric surgery is a statutory benefit. The drug is not. That gap is exactly what the petition behind a November 2025 decision of the Bundestag’s petitions committee was about: the petitioner argued that stomach reduction surgery plus lifelong follow-up costs more than lifelong drug treatment. On 12 November 2025 the committee decided, by a broad majority, that reimbursement in cases of medical necessity was “worth considering”, and recommended forwarding the petition to the Federal Health Ministry “as material”. In its reasoning it pointed straight back at section 34 and the lifestyle category, and said conclusive long-term data on cardiovascular endpoints and drug safety should be awaited.

Worth considering and as material are the parliamentary vocabulary for nothing happening yet. Nine months later, nothing has. And because the G-BA has already stated that it has no discretion, this cannot be fixed by the committee that made the listing. Changing it means changing the statute, which is a job for the legislature, not the regulator.

Where German coverage stands, checked on 9 September 2026

A lot of half-accurate information circulates about this rule. So here is what actually applies, every line read at the primary source, every line dated. We will keep this section current, and leave it standing when nothing moves.

What applies	Status	Source
Statutory exclusion: section 34(1) SGB V, sentences 7 and 8	version in force, read 9 Sep 2026	gesetze-im-internet.de, § 34 SGB V
Implementation: Annex II of the medicines directive (lifestyle drugs)	last amendment in force since 20 Aug 2025	G-BA, Annex II to section F
Wegovy (semaglutide), weight-reduction indication	excluded; decided 21 Mar 2024, in force 15 Jun 2024	G-BA decision 6513, BAnz AT 14.06.2024 B4
Mounjaro (tirzepatide), weight-reduction indication	excluded; decided 19 Sep 2024, in force 13 Dec 2024	G-BA decision 6812, BAnz AT 12.12.2024 B3
Saxenda (liraglutide), weight-reduction indication	excluded	Annex II, ATC A 08 AX 02 and A 10 BJ 02
Wegovy tablet (oral semaglutide)	EU authorisation extended in 2026; no new entry in Annex II	EMA, Wegovy EPAR, procedure X/0000296344
Same substances for type 2 diabetes	not caught by the exclusion	Annex II, qualifier “only when used for weight reduction”
Political state of play	petition sent to the health ministry “as material” on 12 Nov 2025; G-BA chair called for a review on 2 Aug 2026	Bundestag, hib on petition 165851; Der Spiegel 32/2026
France, for comparison	65 percent reimbursement since 15 Jun 2026	Service-Public.fr, ameli.fr

What the exclusion actually attaches to

Annex II does not list injections or packs. It lists active substances by their ATC code. Semaglutide appears under A 08 AX 03 and A 10 BJ 06, each with the qualifier that the entry applies only to use for weight reduction; the adjacent column, headed “finished medicinal products, all strengths”, names Wegovy. Tirzepatide sits under A 10 BX 16 with Mounjaro, liraglutide under A 08 AX 02 and A 10 BJ 02 with Saxenda. So the exclusion hangs on the substance and the indication, not on the delivery form and not on the dose.

On our reading, the tablet changes none of this

On 22 May 2026 the European Medicines Agency’s human medicines committee recommended extending the Wegovy authorisation to cover a tablet. For that extension, procedure number X/0000296344, the EMA records 14 July 2026 as the date of the procedure that last changed the product information; the manufacturer dates the European Commission decision to 15 July 2026. We give both dates because we have not read the Commission decision itself in full.

For German statutory insurance, the way the annex is built means nothing changes: same substance, same indication, same product name, and the column explicitly covers all strengths. Annex II was last amended on 20 August 2025, that is, before the tablet was authorised, and on 9 September 2026 we found no separate decision on the oral form in the list of Annex II decisions. That is our reading of the documents, not a statement from the committee.

A footnote for anyone checking the citation

The sentence numbering in section 34(1) SGB V is cited inconsistently. For the clause excluding medicines whose use is primarily about increasing quality of life, the G-BA cites sentence 7. The Bundestag’s petitions committee cites sentence 8 for the same clause. In the wording in force on 9 September 2026, sentence 7 is the quality-of-life clause and sentence 8 is the list that puts slimming, appetite suppression and body-weight regulation alongside erectile dysfunction, smoking cessation and hair growth. If you are checking a citation, read the wording rather than the sentence number.

What has moved politically, and what has not

On 2 August 2026 Sonja Optendrenk, chair of the Federal Joint Committee since the start of July 2026, gave an interview to Der Spiegel, which ran it under her line that Germany is having a backward discussion about obesity. She called it worth considering to recognise weight-loss drugs as a statutory benefit under certain conditions, and added a caveat: as long as the weight comes straight back after stopping, an injection on its own is not a model of care. The interview is behind a paywall; we read the headline quote on the Spiegel teaser page and the other two in Der Tagesspiegel’s report of the same day, and we translated them ourselves. We flag that rather than blur it.

It still needs placing. This is an interview, not a decision and not an announcement. Optendrenk chairs the body that stated in 2024 that it has no discretion here. If that assessment holds, the chair cannot lift the listing either; that would take the legislature amending section 34. The intervention matters as a signal, not as a procedural step.

On the other side sits the petition. On 12 November 2025 the petitions committee recommended forwarding it to the Federal Health Ministry “as material”, so that it could be taken into account in considerations about improving the situation of those affected. We found no response from the ministry up to 9 September 2026. We are not claiming there is none; we have no solid source for one.

And the limit of this section is the limit of the whole piece: nothing here says anyone should take these drugs. It says how the rule is built, who could change it, and who has not.

Why we are writing about this at all

Fatosphere does not tell anyone to take these drugs, and we do not treat weight loss as a goal worth pursuing. Our interest in GLP-1 policy has always been the same one: what it reveals about who is allowed access to medical care, and on what terms.

Until now we could only tell that story with American material, where private insurers, Medicaid programmes and federal pilots open and close the door month by month. France and Germany let us tell it inside one continent, under two systems that both claim to cover everyone. A person with the same body, the same diagnoses and the same doctor gets a different answer depending on which side of the Rhine they live on. That is not medicine. That is administrative geography.

And the German category is worth naming for what it is. Placing body weight in a legal list with hair growth and sexual potency was a political choice made in 2004, at a time when almost none of the current evidence existed. It has since become a rule that its own enforcers say they cannot bend. Whatever you think about these drugs, and there are good reasons for scepticism about a market this loud, a health system that decides in advance that the topic is a matter of lifestyle has stopped asking the medical question. It has just made the answer someone else’s problem.

What we are watching

• Whether the Federal Health Ministry does anything with the petition it received as material in November 2025.
• Whether France’s narrow criteria hold, and who ends up excluded by the requirement to have documented a failed diet first.
• Whether other EU states follow one model or the other, which will show whether the French decision was an outlier or the beginning of a split.

Related reading

Our earlier work on the same question, from the American side: Fat and Poor: The GLP-1 Access Gap Punishes Twice. On rights in and outside the doctor’s office: When the World Isn’t Built for You: Weight Discrimination, and What to Do About It and What to Do When a Doctor Blames Everything on Your Weight.

Sources

• Service-Public.fr (Direction de l’information légale et administrative), “Deux médicaments contre l’obésité remboursés depuis le 15 juin”, published 1 June 2026, updated 15 June 2026.
• Assurance Maladie (ameli.fr), “Obésité : de nouveaux médicaments peuvent être pris en charge dans des conditions encadrées”, 16 June 2026.
• Section 34 of the German Social Code Book V (SGB V), full text at gesetze-im-internet.de.
• Gemeinsamer Bundesausschuss, press release, “G-BA vollzieht den gesetzlichen Verordnungsausschluss für das Abmagerungsmittel Wegovy nach”, 21 March 2024.
• Gemeinsamer Bundesausschuss, professional news item, “Tirzepatid und Ritlecitinib als Lifestyle-Arzneimittel gelistet”, 20 September 2024, on the decision of 19 September 2024.
• Deutscher Bundestag, hib 605/2025, “Übernahme der Kosten für die Abnehmspritze durch die GKV”, 12 November 2025, on petition ID 165851.
• Section 34 SGB V, full text at gesetze-im-internet.de, read 9 September 2026.
• Gemeinsamer Bundesausschuss, Annex II to section F of the medicines directive (lifestyle drugs), version with the last amendment in force since 20 August 2025, read 9 September 2026.
• Gemeinsamer Bundesausschuss, decision 6513 (semaglutide/Wegovy), decided 21 March 2024, in force 15 June 2024, BAnz AT 14.06.2024 B4.
• Gemeinsamer Bundesausschuss, decision 6812 (tirzepatide/Mounjaro and ritlecitinib/Litfulo), decided 19 September 2024, in force 13 December 2024, BAnz AT 12.12.2024 B3.
• European Medicines Agency, news item “First oral GLP-1 treatment for weight management”, 22 May 2026, and the Wegovy EPAR page, procedure X/0000296344, read 9 September 2026.
• Der Spiegel 32/2026, interview by Martin U. Müller with Sonja Optendrenk, 2 August 2026 (paywalled); additionally Der Tagesspiegel, “Adipositas ist eine echte Krankheit”, 2 August 2026, for the passages quoted there.